Why is Glenmark Pharma falling/rising?

As of 16-Sep, Glenmark Pharmaceuticals Ltd. is currently priced at 2,076.55, reflecting a decrease of 21.8 points or 1.04%. The stock has been underperforming, having fallen consecutively for the last two days, resulting in a total decline of 2.26% during this period. Additionally, the stock's performance today has underperformed its sector by 1.32%. Despite a strong historical performance, with a 29.07% increase year-to-date and a remarkable 457.46% rise over the last three years, recent trading activity indicates a decline in investor participation, with delivery volume dropping by 34.8% compared to the five-day average. The stock remains liquid enough for trading, but its current moving averages suggest a mixed outlook, being higher than longer-term averages but lower than the five-day average.
In the broader market context, Glenmark's short-term return of -1.77% over the past week contrasts sharply with the Sensex, which has gained 1.58% during the same period. This divergence highlights the stock's recent struggles relative to the overall market. While the company benefits from strong institutional holdings and a favorable debt-to-EBITDA ratio, which supports its ability to service debt, the recent decline in trading volume and consecutive price drops may be causing concern among investors. Overall, while the company has demonstrated consistent returns and outperformed the BSE500 over the past three years, the current market sentiment appears to be weighing on its stock price.